Literature DB >> 35663657

Estimation of Value-Based Price for Five High-Technology Medical Devices Approved by a Regional Health Technology Assessment Committee in Italy.

Andrea Messori1, Sabrina Trippoli1.   

Abstract

Background and objectives Value-based pricing (VBP) is used quite frequently for medicines, but its application to medical devices is very limited. The objective of the present study was to conduct a pilot experience of systematic estimation of the value-based price of medical devices from the perspective of our national health system. Our experience was focused on high-technology devices (class IIb/III and active implantable). The objective was to evaluate the applicability of VBP in a real-world setting and to estimate the value-based price of devices in all cases where this estimation was feasible. Methods The dataset analysed in this work consists of 24 new devices approved consecutively in the Tuscany region over the period from January 2020 to December 2021. Since the calculation of value-based price requires the availability of a cost-effectiveness analysis, we searched for this information for each of these devices. The Cost-Effectiveness Analysis (CEA) Registry of Tufts Medical Center (US) and the health technology assessment (HTA) reports of our region were considered adequate sources of these data. Standard equations of cost-effectiveness were applied to determine the value-based price for these devices, and these prices were compared with the corresponding real prices charged in our region. Results We found adequate information for five devices (21%) out of the total of 24. In three of these cases, the published analysis taken as a reference was based on Markov modelling. The comparison between value-based prices and real prices generally showed an acceptable concordance, though with a couple of outliers. An important finding is that, in a large proportion of cases (79%), the information needed for this calculation was lacking. Conclusion To our knowledge, this is the first experience in which an institution of the healthcare system has tried a systematic application of VBP in the field of high-technology devices. Our results are encouraging and suggest a wider application of cost-effectiveness in this field.
Copyright © 2022, Messori et al.

Entities:  

Keywords:  cost-effectiveness; medical devices; quality-adjusted life years; value-based price; willingness-to-pay threshold

Year:  2022        PMID: 35663657      PMCID: PMC9162886          DOI: 10.7759/cureus.24695

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  20 in total

1.  Regulation of medical devices in the United States and European Union.

Authors:  Daniel B Kramer; Shuai Xu; Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2012-02-14       Impact factor: 91.245

2.  Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation.

Authors:  Maurizio Taramasso; Giovanni Benfari; Pieter van der Bijl; Hannes Alessandrini; Adrian Attinger-Toller; Luigi Biasco; Philipp Lurz; Daniel Braun; Eric Brochet; Kim A Connelly; Sabine de Bruijn; Paolo Denti; Florian Deuschl; Rodrigo Estevez-Loureiro; Neil Fam; Christian Frerker; Mara Gavazzoni; Jörg Hausleiter; Edwin Ho; Jean-Michel Juliard; Ryan Kaple; Christian Besler; Susheel Kodali; Felix Kreidel; Karl-Heinz Kuck; Azeem Latib; Alexander Lauten; Vanessa Monivas; Michael Mehr; Guillem Muntané-Carol; Tamin Nazif; Georg Nickening; Giovanni Pedrazzini; François Philippon; Alberto Pozzoli; Fabien Praz; Rishi Puri; Josep Rodés-Cabau; Ulrich Schäfer; Joachim Schofer; Horst Sievert; Gilbert H L Tang; Holger Thiele; Yan Topilsky; Karl-Philipp Rommel; Victoria Delgado; Alec Vahanian; Ralph Stephan Von Bardeleben; John G Webb; Marcel Weber; Stephan Windecker; Mirjam Winkel; Michel Zuber; Martin B Leon; Rebecca T Hahn; Jeroen J Bax; Maurice Enriquez-Sarano; Francesco Maisano
Journal:  J Am Coll Cardiol       Date:  2019-09-27       Impact factor: 24.094

3.  Implementation of Value-based Pricing for Medicines.

Authors:  Claudio Jommi; Patrizio Armeni; Francesco Costa; Arianna Bertolani; Monica Otto
Journal:  Clin Ther       Date:  2019-12-24       Impact factor: 3.393

4.  Tenders for the Procurement of Medical Devices: Adapting Cost-Effectiveness Rules to the Requirements of the European Public Procurement Directive.

Authors:  Andrea Messori; Sabrina Trippoli; Erminia Caccese; Claudio Marinai
Journal:  Ther Innov Regul Sci       Date:  2020-01-06       Impact factor: 1.778

5.  Presentation, Diagnosis, and Outcomes of Acute Aortic Dissection: 17-Year Trends From the International Registry of Acute Aortic Dissection.

Authors:  Linda A Pape; Mazen Awais; Elise M Woznicki; Toru Suzuki; Santi Trimarchi; Arturo Evangelista; Truls Myrmel; Magnus Larsen; Kevin M Harris; Kevin Greason; Marco Di Eusanio; Eduardo Bossone; Daniel G Montgomery; Kim A Eagle; Christoph A Nienaber; Eric M Isselbacher; Patrick O'Gara
Journal:  J Am Coll Cardiol       Date:  2015-07-28       Impact factor: 24.094

6.  Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.

Authors:  Alyssa Bilinski; Evan MacKay; Joshua A Salomon; Ankur Pandya
Journal:  Value Health       Date:  2022-02-24       Impact factor: 5.101

7.  Incremental cost-effectiveness of percutaneous versus surgical closure of atrial septal defects in children under a public health system perspective in Brazil.

Authors:  Rodrigo Costa; Carlos A C Pedra; Marcelo Ribeiro; Simone Pedra; André Luis Ferreira-Da-Silva; Carisi Polanczyk; Otávio Berwanger; Alexandre Biasi; Rodrigo Ribeiro
Journal:  Expert Rev Cardiovasc Ther       Date:  2014-10-04

8.  Relationship Between Price and Diagnosis-Related Group Tariff for Medical Devices Assessed by a Regional Health Technology Assessment Committee.

Authors:  Sabrina Trippoli; Andrea Messori; Giovanna Borselli; Filomena Autieri; Domenica Mamone; Claudio Marinai
Journal:  Cureus       Date:  2022-03-12

9.  Midterm Outcomes of the Dissected Aorta Repair Through Stent Implantation Trial.

Authors:  Sabin J Bozso; Jeevan Nagendran; Michael W A Chu; Bob Kiaii; Ismail El-Hamamsy; Maral Ouzounian; Jörg Kempfert; Christoph Starck; Michael C Moon
Journal:  Ann Thorac Surg       Date:  2020-07-13       Impact factor: 4.330

10.  Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.

Authors:  Jörg Ruof; Friedrich Wilhelm Schwartz; J-Matthias Schulenburg; Charalabos-Markos Dintsios
Journal:  Eur J Health Econ       Date:  2013-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.